Miniaturized Drug Sensitivity and Resistance Test on Patient-Derived Cells Using Droplet-Microarray

Area of Science:

• Biotechnology
• Oncology
• Microfluidics

Background:

• Ex vivo drug sensitivity testing aids personalized cancer treatment.
• Limited patient-derived tumor cells hinder conventional testing methods.

Purpose of the Study:

• To develop a novel platform for ex vivo drug sensitivity testing using minimal patient-derived tumor cells.
• To enable precision medicine by facilitating drug resistance screening.

Main Methods:

• Introduction of a Droplet-Microarray platform with a hydrophilic-superhydrophobic patterned surface.
• Screening of patient-derived chronic lymphocytic leukemia (CLL) cells using nanoliter-sized droplets.
• Utilizing only 100 cells and 30 picomoles of drug per droplet for dose-response assays.

Main Results:

• The Droplet-Microarray platform successfully performed dose-response assays with as few as 100 primary patient-derived CLL cells.
• Results from the miniaturized platform closely mimicked those from conventional 384-well plates requiring 20,000 cells.
• Demonstrated feasibility of drug sensitivity and resistance testing on limited tumor cell samples.

Conclusions:

• The Droplet-Microarray platform significantly reduces the number of cells and drug quantity required for ex vivo testing.
• This technology holds substantial potential for advancing precision medicine through practical ex vivo drug sensitivity and resistance assessments.
• Facilitates personalized treatment strategies by enabling analysis of rare patient-derived tumor cells.